지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.9
- 수록면
- 539 - 545 (7page)
- DOI
- https://doi.org/10.4111/icu.20220179
이용수
초록· 키워드
오류제보하기
Purpose: Intravesical Bacillus Calmette?Guerin (BCG) instillation, although an important treatment for non-muscle-invasive bladder cancer, exerts local and systemic adverse effects. Pentosan polysulfate (PPS) is a bladder mucosal protective drug that acts by replacing mucus in the glycosaminoglycan layer of the damaged urothelium. We hypothesized that co-administration of oral PPS with BCG instillation would relieve BCG-related adverse effects without affecting its efficacy.
Materials and Methods: A total of 217 patients receiving BCG instillation were enrolled. They were placed in two groups and analyzed retrospectively: group A (n=122) received BCG instillation only and group B (n=95) received 100 mg of PPS thrice daily during the BCG treatment.
Results: After BCG instillation, the rate of BCG-treatment discontinuation owing to adverse effects was 15.6% in group A and 6.3% in group B (p=0.034). The proportion of patients with bacteriuria after BCG was higher in group B; however, no statistical difference was observed (28.7% vs. 41.1%; p=0.057). The proportion of patients with pyuria was significantly higher in group B (81.1% vs. 91.6%; p=0.029). The proportion of patients using antibiotics was significantly higher in group A (73.8% vs. 43.2%; p=0.001). The recurrence rate within 1 year was 29 (23.8%) in group A vs. 19 (20.0%) in group B (p=0.507). Univariate and multivariate analyses showed that antibiotic use had a statistically significant effect on BCG discontinuation.
Conclusions: Oral PPS effectively decreased the discontinuation rate and antibiotic use without affecting the BCG efficacy.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
A possible protective role for Bacillus Calmette-Guérin therapy in urinary bladder cancer in the era of COVID-19: a brief report
Clinical and Experimental Vaccine Research
2021 .01
-
The Development of Pentosan Polysulfate for the Mucopolysaccharidoses : from Animal Models to Clinical Trials
한국실험동물학회 학술발표대회 논문집
2015 .08
-
Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms
대한암예방학회지
2024 .03
-
Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study
Investigative and Clinical Urology
2024 .05
-
Low-dose versus standard-dose bacille Calmette?Guerin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials
Investigative and Clinical Urology
2022 .03
-
Rates and Risk Factors of Bacteriuria in Patients with Bladder Cancer Who Underwent Treatment with Bacillus Calmette-Guerin
Urogenital Tract Infection
2020 .01
-
Antitumor effects of intravesical treatment on bacillus calmette-guerin cell wall cytoskeleton with encapsulated liposome in orthotopic mouse model of bladder cancer
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Results of Intravesical Chemo-Hyperthermia in High-risk Non-muscle Invasive Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review
Investigative and Clinical Urology
2020 .01
-
Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography
Urogenital Tract Infection
2017 .01
-
Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
Investigative and Clinical Urology
2021 .01
-
Severity of COVID-19 in bacillus Calmette-Guerin vaccinated population
Clinical and Experimental Vaccine Research
2021 .09
-
Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea
Investigative and Clinical Urology
2024 .09
-
Granulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder Cancer
Nuclear medicine and molecular imaging : NMMI
2016 .01
-
Performance of the Sysmex UF-1000i System in Screening for Significant Bacteriuria in Patients with Bladder Cancer Who Received Bacillus Calmette-Guerin Treatment
Urogenital Tract Infection
2020 .01
-
Previous Bladder Cancer History in Patients with High-Risk, Non–muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History
Cancer Research and Treatment
2015 .01
-
Feasibility of Photodynamic Diagnosis for Challenging TUR-Bt Cases Including Muscle Invasive Bladder Cancer, BCG Failure or 2<sup>nd</sup>-TUR
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Chronic Infections of the Urinary Tract and Bladder Cancer Risk: a Systematic Review
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
Investigative and Clinical Urology
2023 .03
-
Genetic and Epigenetic Alterations in Bladder Cancer
International Neurourology Journal
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0